| Zacks Company Profile for Nutra Pharma Corp. (NPHC : OTC) |
|
|
| |
| • Company Description |
| Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company operates through its subsidiaries and carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma currently offers several drug products for sale for the treatment of pain: Cobroxin, the over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, the non-narcotic and non-addictive treatment for severe (Stage 3) pain. In addition, the Company is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases. Nutra Pharma Corporation is based in Boca Raton, Florida.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.00 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 55,436 shares |
| Shares Outstanding: 7,099.74 (millions) |
| Market Capitalization: $0.71 (millions) |
| Beta: -0.23 |
| 52 Week High: $0.00 |
| 52 Week Low: $0.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
% |
% |
| 12 Week |
-50.00% |
-59.11% |
| Year To Date |
% |
% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Rik J. Deitsch - Chairman; President and Chief Executive Office
Garry R. Pottruck - Director
Stewart Lonky - Director
Harold Rumph - Director
Dan Oran - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 67060U208
SIC: 2833
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding: 7,099.74
Most Recent Split Date: 5.00 (0.03:1)
Beta: -0.23
Market Capitalization: $0.71 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: - |
|
|
|
| |
